TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07309055: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd · Phase: PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 201 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,723,520

Rescue Site Savings

+$7,730,196

Unlock Full NCT07309055 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07309055 Rescue Dossier →